Genmab A/S (Nasdaq: GMAB, 0MGB), the Copenhagen-headquartered international biotechnology company, announced on 18 November 2026 that its Board of Directors had approved the grant of 4,993 restricted stock units (RSUs) and 4,607 warrants to employees across the company and its subsidiaries. Both instruments were awarded cost-free, with each RSU and each warrant carrying a grant-date reference price of DKK 3,496 per share. The disclosure forms part of Genmab's ongoing equity compensation programmes and provides insight into how the antibody medicines specialist is retaining and incentivising its global workforce.

Key Points

  • Genmab A/S (Nasdaq: GMAB, 0MGB) — Danish biotechnology company established in 1999 and dedicated to antibody-based cancer medicines
  • The Board of Directors granted 4,993 RSUs and 4,607 warrants to employees of the company and its subsidiaries on 18 November 2026
  • RSUs vest on the first banking day of the month following three years from the grant date; warrants also vest after three years and expire at the seventh anniversary of the grant date
  • Investors may wish to monitor how equity-based compensation aligns with Genmab's late-stage clinical pipeline progress and long-term retention strategy

RSU Terms: DKK 3,496 Fair Value and Three-Year Vesting Tied to Genmab's Board Programme

Each of the 4,993 restricted stock units entitles the recipient to receive one Genmab A/S share of nominally DKK 1, awarded at no cost to the employee. The fair value of each RSU equals the closing market price on the grant date, set at DKK 3,496. Vesting occurs on the first banking day of the month following a three-year period from the grant date, subject to conditions established under the RSU programme adopted by the Board of Directors. Full details of these vesting conditions are publicly available on Genmab's investor relations website under the Compensation section.

Warrant Exercise Price Fixed at DKK 3,496 with Black-Scholes Fair Value of DKK 1,230.13

The 4,607 warrants granted carry an exercise price of DKK 3,496 each, with each warrant entitling the holder to subscribe for one share of nominally DKK 1 upon payment of that exercise price. Applying the Black-Scholes formula, the announcement states the fair value of each warrant is DKK 1,230.13. The warrants vest three years after the grant date and expire at the seventh anniversary. They were granted under the warrant programme adopted by the Board of Directors on 23 February 2021.

Genmab's Antibody Pipeline and Global Footprint Underpin the Equity Incentive Structure

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates across North America, Europe and Asia Pacific. The company's science underpins eight approved antibody medicines, spanning bispecific antibodies, antibody–drug conjugates, and immune-modulating antibodies. Genmab is also advancing a late-stage wholly owned clinical pipeline targeting cancer and other serious diseases. Equity programmes of this nature are common tools in the biotechnology sector for retaining specialist scientific and commercial talent during lengthy drug development cycles, where human capital represents a material operational risk.